ライフサイエンスコーパス: humanized antibody

1 ht chain of hLL1, an internalizing anti-CD74 humanized antibody.

2 ments next to human framework regions in the humanized antibody.

3 ith immunosuppressive drugs or the use of a "humanized" antibody.

4 kg have a half-life similar to that of other humanized antibodies.

5 ut there were no detectable responses to the humanized antibody (0 of 12).

6 by combining these treatments with unlabeled humanized antibodies against CD22 (epratuzumab), CD74 (m

7 mmune modulators (exogenous glucocorticoids, humanized antibodies against cytokines) may decrease dep

8 rowth promoting signals and that therapeutic humanized antibodies against EGFR and HER2 can effective

9 combinations include apolizumab (Hu1D10), a humanized antibody against an epitope of HLA-DR, and IDE

10 Infliximab is a humanized antibody against tumor necrosis factor alpha (

11 a versatile approach for generating human or humanized antibody agonists with excellent pharmacologic

12 Using newly developed humanized antibodies and conditional genetic models, we

13 Many humanized antibodies and fusion proteins targeting T-cel

14 ant forms of complement regulatory proteins, humanized antibodies, and synthetic molecules have been

15 As a result, chimeric as well as totally humanized antibodies are currently being evaluated as th

16 oxin were grafted into different CDRs of the humanized antibodies BVK and Synagis (Syn) using both be

17 splay method for optimizing the framework of humanized antibodies by random mutagenesis of important

18 ctions and the development of hypoantigenic "humanized" antibodies by genetic engineering, which then

19 hough these properties could be blocked by a humanized antibody directed against human endosialin/TEM

20 and HER2 by chemical FAS inhibitors and the humanized antibody directed against p185(HER2) trastuzum

21 Starting with a partially humanized antibody, DMB5F3, we created a recombinant chi

22 The Fab portion of a humanized antibody (Fab-12; IgG form known as rhuMAb VEG

23 Abs in which the tumor cell specificity of a humanized antibody fragment that recognizes CD3 on T cel

24 ed for the rapid generation of high-affinity humanized antibodies from immunized animals without the

25 Indeed, humanized antibodies hAb47 and hAb131 showed similar aff

26 Although humanized antibodies have been highly successful in the

27 Genetically engineered chimeric and humanized antibodies have demonstrated activity against

28 e native hormones into different CDRs of the humanized antibody Herceptin.

29 was shown that the terminal half-life of the humanized antibody in rhesus monkeys is 14-20 days, with

30 A recombinant humanized antibody-interleukin 2 fusion protein (huKS1/4

31 with cancer, and the immunogenicity of the "humanized" antibody is sufficiently reduced relative to

32 er before or after exposure to MERS-CoV, the humanized antibody may prevent or inhibit MERS-CoV infec

33 ers of PD-L1 inhibition using the engineered humanized antibody MPDL3280A.

34 recombinant antibody technology, which makes humanized antibody or human-mouse chimeric antibody avai

35 odies may be candidates for treatment with a humanized antibody preparation such as daclizumab in the

36 This humanized antibody represents an attractive candidate fo

37 The recombinant humanized antibody (rhuMAb) VEGF has a high affinity for

38 he requirement to construct and analyze each humanized antibody separately.

39 RG7356 is a humanized antibody targeting the constant region of CD44

40 allows the generation of high affinity human/humanized antibodies that can be optimized for antibacte

41 rapeutics based on blocking eosinophils with humanized antibodies that neutralize IL-5, a potent eosi

42 A humanized antibody that binds to pig and human CD163 was

43 ested the clinical efficacy of eculizumab, a humanized antibody that inhibits the activation of termi

44 In conclusion, H3L2 is an ideal humanized antibody that inhibits tumor growth through ta

45 Pertuzumab, a humanized antibody that prevents HER2 dimerization and i

46 deleted CC49 (HuCC49DeltaCH2), a recombinant humanized antibody that recognizes the TAG-72 antigen ex

47 This ADC is based on a humanized antibody that selectively binds with high affi

48 huA33 is a humanized antibody that targets the A33 antigen, which i

49 For humanized antibodies, the assignment of the frameworks i

50 mework mutations that improve the binding of humanized antibodies to their cognate antigens and may p

51 acid)-conjugated, (111)In- and (90)Y-labeled humanized antibody to CD22, epratuzumab, was studied in

52 We evaluated CDP571, a humanized antibody to tumor necrosis factor, for the tre

53 al antibody technology one can now produce a humanized antibody to virtually any target antigen that

54 this unique "stalk-knob" architecture to the humanized antibody trastuzumab (referred to hereafter by

55 target for personalized treatment using the humanized antibody trastuzumab.

56 A high affinity humanized antibody was derived that was considerably mor

57 antibody response, two chimeric and several humanized antibodies were constructed for evaluation.

58 The resulting humanized antibodies were found to retain both high spec

59 Humanized antibodies will achieve greater intensity and

60 affinity for antigen relative to the initial humanized antibody with no framework changes.

61 zumab is a glycoengineered, type 2 anti-CD20 humanized antibody with single-agent activity in relapse